Twitter’s reach and ability to influence have made it a critical communication tool in all areas of life and work. Learn how UCSF cancer experts are harnessing the value of Twitter's bite-sized benefits.
UCSF Medical Center has been recognized as the nation’s best hospital for neurology and neurosurgery, and among the country’s premier medical centers overall, in the 2021-22 Best Hospitals survey by U.S. News & World Report.
Thirteen investigators were awarded grants in support of cancer research projects in the Spring 2021 cycle of the UCSF Resource Allocation Program (RAP), spanning a range of topics from health equity to therapy resistance to developing new screening methods.
The idea of using cells as medicine emerged with bone marrow transplants, and then CAR-T therapy for blood cancers. Now, scientists are beginning to engineer much more complex living therapeutics by tapping into the innate capabilities of living cells to treat a growing list of diseases.
A recent FDA-approved treatment for non-small cell lung cancer rests on a foundation of work by UCSF scientists. As a result, drugging other KRAS-driven cancers is no longer unthinkable.
A recent collaborative retrospective cohort study from UC San Francisco, UC Davis and others confirmed that Down syndrome remains a strong risk factor for childhood leukemia, and associations with AML are stronger than previously reported.
UC San Francisco is launching a new initiative to propel the development of living therapeutics – a category of treatments broadly defined as human and microbial living cells that are selected, modified, or engineered to treat or cure disease – and bring them quickly to patients.